Sanofi

News and Events

Press Releases


June 12, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

June 10, 2026
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

June 8, 2026
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Upcoming Events

30Jul

2026

Second quarter 2026 results

Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.

13:00 - 14:15 CET (7:00am - 8:15am EST)

Quarterly results


30Oct

2026

Third quarter 2026 results

Third quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on October 30, 2026. The presentation will be followed by a Q&A session.

Quarterly results


Past Events

23Apr

2026

First quarter 2026 results

Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.

Quarterly results

Discover more

29Jan

2026

Fourth quarter & full year 2025 results

Fourth quarter and full year 2025 results were reviewed by management during a live audio webcast with the financial community on January 29, 2026. The presentation was followed by a Q&A session.

Quarterly results

Discover more

24Oct

2025

Third quarter 2025 results

Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.

Quarterly results

Discover more